The present invention relates to a continuous process for preparing permselective hollow fiber membranes being suitable e.g. for hemodialysis, hemodiafiltration and hemofiltration of blood which comprises a two-stage drying and tempering treatment of the hollow fiber membranes. According to a further aspect, the invention relates to a continuous process for drying permselective hollow fiber membranes on-line. The invention also relates to devices for on-line drying of permselective hollow fiber membranes.

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and/or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.

A blood isolation and extraction method includes: providing a predetermined amount of blood; utilizing a platelet filter unit to filter the predetermined amount of blood to generate a filtered blood; utilizing a plasma separation unit to divide the filtered blood into a plasma layer and a blood cell layer for separating blood cells from blood plasma; and extracting the blood plasma from the plasma layer and the blood cells from the blood cell layer. In another embodiment, the blood isolation and extraction method further includes: providing a platelet-washing unit to wash the platelet filter unit with a solution to produce a platelet solution; and mixing the platelet solution with the blood plasma to produce a platelet and plasma mixed solution.

Conventional single fraction 20-Gy broadbeam photonbeam or protonbeam chemo-radiosurgery does not sterilize EMT-MET cancer stem cell radiodurans but single fraction 100 to 10,000 Gy microbeam radiosurgery sterilizes them. Device and methods for microbeam chemo-radiosurgery including 250 MeV wakefield electronbeam is disclosed.

Surgery, chemotherapy and broadbeam and microbeam radiosurgery releases billions of abscopal metastasis causing, tumor specific plasma soluble proteins, cell membranes, apoptotic bodies, DNA and RNAs, exosomes like telomere-telomerase, ATM-ATM kinase and others. They and adaptive resistance to chemo-radiosurgery, paraneoplastic and non-paraneoplastic diseases causing immune complexes are removed by pulse flow combined continuous flow ultracentrifugation apheresis and immune affinity chromatography. Chemotherapy and high dose radiation exposed tumor cells and their exosomes are made sensitive to telomerase inhibiting and apoptosis inducing and least toxic epigallocatechin and to heparin bound receptors. They convert triple negative breast tumors into receptor positive tumors which open new avenues for treating most aggressive breast cancers.

A wearable ultrafiltration apparatus is provided. The apparatus can include a first dialyzer for filtering a patient's blood along a first fluid path and a second dialyzer for filtering the patient's blood along a second fluid path. The apparatus can also include a valve being positionable in a first position for directing the patient's blood along the first fluid path. The valve can also be positioned in a second position for directing the patient's blood along the second fluid path. When the valve is in the first position, blood can flow along the first fluid path and prevent blood from flowing along the second fluid path. When the valve is in the second position, blood can flow along the second fluid path and prevent blood from flowing along the first fluid path. When the valve is in the first position, the second dialyzer can be idle and capable of being serviced or replaced and when the valve is in the second position, the first dialyzer can be idle and capable of being serviced or replaced. Therefore, when a dialyzer fouls, blood can be directed to the other dialyzer while the fouled dialyzer is being serviced or replaced.

A wearable ultrafiltration apparatus is provided. The apparatus can include a first dialyzer for filtering a patient's blood along a first fluid path and a second dialyzer for filtering the patient's blood along a second fluid path. The apparatus can also include a valve being positionable in a first position for directing the patient's blood along the first fluid path. The valve can also be positioned in a second position for directing the patient's blood along the second fluid path. When the valve is in the first position, blood can flow along the first fluid path and prevent blood from flowing along the second fluid path. When the valve is in the second position, blood can flow along the second fluid path and prevent blood from flowing along the first fluid path. When the valve is in the first position, the second dialyzer can be idle and capable of being serviced or replaced and when the valve is in the second position, the first dialyzer can be idle and capable of being serviced or replaced. Therefore, when a dialyzer fouls, blood can be directed to the other dialyzer while the fouled dialyzer is being serviced or replaced.

The invention provides apheresis devices and their use for substantial removal of all types of cfDNA for treatment of various diseases and during perfusion of an organ and/or anatomical cavity, to limit the negative effects of circulating cfDNA during organ transplantation and thus improve the quality and survival of transplanted organs, and reduce unfavorable transplantation outcomes such as transplant dysfunction, ischemia-reperfusion injury, graft rejection, and organ failure.

The invention provides apheresis devices and their use for substantial removal of all types of cfDNA for treatment of various diseases and during perfusion of an organ and/or anatomical cavity, to limit the negative effects of circulating cfDNA during organ transplantation and thus improve the quality and survival of transplanted organs, and reduce unfavorable transplantation outcomes such as transplant dysfunction, ischemia-reperfusion injury, graft rejection, and organ failure.

Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

The present invention relates to an organizer for releasably accommodating components of blood tube sets for different extracorporeal blood treatment options, in particular for dialysis methods, by means of a blood treatment apparatus, as well as methods for manufacturing and preparing an organizer of the invention.